| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000022698 |
| Receipt No. | R000007082 |
| Official scientific title of the study | Effect of Clostridium butyricum on Clostridium difficile in the fecus due to antibiotics:randomized prospective study |
| Date of disclosure of the study information | 2016/06/11 |
| Last modified on | 2016/06/11 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Effect of Clostridium butyricum on Clostridium difficile in the fecus due to antibiotics:randomized prospective study | |
| Title of the study (Brief title) | Effect of Clostridium butyricum on CD in the fecus due to antibiotics | |
| Region |
|
|
| Condition | ||||
| Condition | bacterial infection administered antibioticsd | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Others | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | The aim of this study is to evaluate efficacy of Clostridium butyricum for prevention of Clostridium difficile in the fecus due to antibiotics |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | CD or CD toxin A/B i nthe fecus after 2 weeks |
| Key secondary outcomes | |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -but assessor(s) are blinded |
| Control | No treatment |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | group with administration of Clostridium butylicum | |
| Interventions/Control_2 | group without administration of Clostridium butylicum | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | bacterial infection administered antibiotics | |||
| Key exclusion criteria | bacterial enterocolitis | |||
| Target sample size | 120 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroyuki Imaeda |
| Organization | Saitama Medical University |
| Division name | Department of General Internal Medicine |
| Address | 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama |
| TEL | 049-276-1667 |
| imaedahi@saitama-med.ac.jp | |
| Public contact | |
| Name of contact person | Hiroyuki Imaeda |
| Organization | Saitama Medical University |
| Division name | Department of General Internal Medicine |
| Address | 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama |
| TEL | 049-276-1667 |
| Homepage URL | |
| imaedahi@saitama-med.ac.jp | |
| Sponsor | |
| Institute | Saitama Medical University |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | none |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007082 |